Development of the serum biomarkers to predict the near-term-risk for cardiovascular disease

点击翻译按钮获取中文摘要

We pay attention to truncated and/or modified apolipoprotein AI(apoAI), such as C-terminally truncated apoAI, N-homocysteinylated apoAI, and apoAI-apoAII heterodimer, as the potential candidates of predictive biomarker for cardiovascular disease. We identified those truncated and modified apoAI in nomal human serum and developed the quantitative methods for those candidates. In the preliminary experiment, the possibility that apoAI-apoAII heterodimer would be a useful biomarker for acute myocardial infarction was indicated.